- Home
- ACIU vs RLTY Comparison
ACIU vs RLTY Comparison
Compare ACIU & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- RLTY
- Stock Information
- Founded
- ACIU 2003
- RLTY 2022
- Country
- ACIU Switzerland
- RLTY United States
- Employees
- ACIU N/A
- RLTY N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- RLTY Investment Managers
- Sector
- ACIU Health Care
- RLTY Finance
- Exchange
- ACIU Nasdaq
- RLTY Nasdaq
- Market Cap
- ACIU 189.1M
- RLTY 251.8M
- IPO Year
- ACIU 2016
- RLTY N/A
- Fundamental
- Price
- ACIU $2.11
- RLTY $15.32
- Analyst Decision
- ACIU Strong Buy
- RLTY
- Analyst Count
- ACIU 1
- RLTY 0
- Target Price
- ACIU $12.00
- RLTY N/A
- AVG Volume (30 Days)
- ACIU 124.6K
- RLTY 86.7K
- Earning Date
- ACIU 08-05-2025
- RLTY 01-01-0001
- Dividend Yield
- ACIU N/A
- RLTY 9.35%
- EPS Growth
- ACIU N/A
- RLTY N/A
- EPS
- ACIU N/A
- RLTY N/A
- Revenue
- ACIU $32,014,254.00
- RLTY N/A
- Revenue This Year
- ACIU N/A
- RLTY N/A
- Revenue Next Year
- ACIU $533.21
- RLTY N/A
- P/E Ratio
- ACIU N/A
- RLTY N/A
- Revenue Growth
- ACIU 91.20
- RLTY N/A
- 52 Week Low
- ACIU $1.43
- RLTY $11.38
- 52 Week High
- ACIU $4.26
- RLTY $14.60
- Technical
- Relative Strength Index (RSI)
- ACIU 59.08
- RLTY 54.90
- Support Level
- ACIU $1.94
- RLTY $15.00
- Resistance Level
- ACIU $2.08
- RLTY $15.49
- Average True Range (ATR)
- ACIU 0.16
- RLTY 0.23
- MACD
- ACIU -0.00
- RLTY 0.01
- Stochastic Oscillator
- ACIU 85.19
- RLTY 65.08
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.